---
title: "Silence Therapeutics: Divesiran and a robust siRNA pipeline target major unmet needs in PV, dyslipidemia, and obesity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290608961.md"
description: "Precision siRNA medicines are advancing for rare and cardiometabolic diseases, with divesiran showing strong efficacy and safety in PV and a robust pipeline targeting dyslipidemia, HoFH, and obesity. Key clinical milestones are expected in 2026 and 2027.Original document: Silence Therapeutics Slides Release — Jun. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-23T20:54:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290608961.md)
  - [en](https://longbridge.com/en/news/290608961.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290608961.md)
---

# Silence Therapeutics: Divesiran and a robust siRNA pipeline target major unmet needs in PV, dyslipidemia, and obesity

Precision siRNA medicines are advancing for rare and cardiometabolic diseases, with divesiran showing strong efficacy and safety in PV and a robust pipeline targeting dyslipidemia, HoFH, and obesity. Key clinical milestones are expected in 2026 and 2027.

Original document: Silence Therapeutics Slides Release — Jun. 23 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [SLN.US](https://longbridge.com/en/quote/SLN.US.md)

## Related News & Research

- [Codexis appoints David Butler to strategic advisory board](https://longbridge.com/en/news/294697266.md)
- [05:30 ETAusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171](https://longbridge.com/en/news/294670779.md)
- [The AI memory boom just got a reality check—and a better entry point](https://longbridge.com/en/news/294587185.md)
- [An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it 'odd'](https://longbridge.com/en/news/294738560.md)
- [The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone](https://longbridge.com/en/news/294635779.md)